Male Infertility Treatment

Male Infertility Treatment Comprehensive Study by Type (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay, Others), Application (Hospitals, Clinics, Others), Treatment (Assisted Reproductive Technology, Varicocele Surgery, Medication, Others), Test (Scrotal ultrasound, Transrectal ultrasound, Hormone testing, Post-ejaculation urinalysis, Genetic tests, Others) Players and Region - Global Market Outlook to 2028

Male Infertility Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Male Infertility Treatment?
Male infertility treatment is a common issue among men. Conception is a difficult process with numerous challenges. Fortunately, having infertility issues does not automatically rule out the possibility of having a child with your partner. There are treatments and procedures that can improve your chances of getting pregnant. Infertility is a problem with your reproductive system that prevents you from becoming pregnant. If a male and a female have had unprotected sex for more than a year and the female does not become pregnant, do not worry if you, she, or both of you have male infertility. Infertility is a common problem, affecting more than five million couples in the United States. One in every six couples attempting to conceive suffers from infertility. A male factor is a major or contributing cause in at least half of all cases of infertility. This means that approximately 10% of all males in the United States who are attempting to conceive are infertile.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBayer Healthcare (Germany), Andrology Solutions (United Kingdom), Aytu BioScience, Inc. (United States), Cadila Healthcare Ltd. (India), Halotech DNA SL (Spain), EMD Sereno, Inc. (United States), SCSA Diagnostics, Inc. (United States), Intas Pharmaceuticals Ltd. (India), The Cooper Companies Inc. (United States) and Vitrolife AB (Sweden)


The study covers a detailed analysis segmented by key business segments i.e. by type (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay and Others) , by application (Hospitals, Clinics and Others) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Male Infertility Treatment market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Male Infertility Treatment market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Bayer Healthcare (Germany), Andrology Solutions (United Kingdom), Aytu BioScience, Inc. (United States), Cadila Healthcare Ltd. (India), Halotech DNA SL (Spain), EMD Sereno, Inc. (United States), SCSA Diagnostics, Inc. (United States), Intas Pharmaceuticals Ltd. (India), The Cooper Companies Inc. (United States) and Vitrolife AB (Sweden).

Market Overview:
On 5th August 2021, Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a biopharmaceutical company based in the United States that uses novel discovery technologies to unlock high-value, previously unreachable targets with precision therapeutics. The Vividion platform is capable of producing a wide range of small molecule therapies across indications, with an initial focus on oncology and immunology targets. Vividion's lead programmes include multiple precision oncology and precision immunology targets, as well as ongoing efforts on a transcription factor NRF2 antagonist for the potential treatment of NRF2 mutant cancers and NRF2 activators for various inflammatory diseases such as irritable bowel disease, among other pre-clinical programmes.
The Indian Council of Medical Research (ICMR) and the National Academy of Medical Sciences (NAMS) have issued National Guidelines for Accreditation, Supervision, and Regulation of ART Clinics in India to regulate and supervise ART clinics. These guidelines were developed following extensive discussion and debate among experts, ART practitioners, and the general public. I have great pleasure in presenting these guidelines, which I believe will be very useful in regulating and supervising the operation of ART Clinics and will assist ART Clinics in providing safe and ethical services to infertile couples in need. I would also like to express our gratitude to the ICMR and NAMS experts who worked tirelessly to develop these guidelines.
This male infertility treatment includes a detailed company profile, product offerings, production graphs, and revenue generated by each company. It also highlights each manufacturer's pricing trends, as well as their respective gross margins and market share during the forecast period. Due to the presence of multiple vendors, the male infertility treatment market is fragmented. Furthermore, advances in male infertility treatment have given women the option of having children later in life, leading to market growth.

Influencing Trend:
Increasing Number of Sperm Donors at Sperm Banks and Growing Awareness through Online Advertisement for Infertility Services

Market Growth Drivers:
Rising Number of Fertility Clinics in Developing Countries and Technological Advancements in Male Infertility Treatment Devices

Challenges:
The High Cost of Procedures

Restraints:
Stringent Government Regulations and Lack of Medical Infrastructure in Underdeveloped Countries

Opportunities:
Growth in Healthcare Infrastructure in Emerging Markets and Demand for Infertility Treatment Options by Same-Sex Couples

Key highlights of the Global Male Infertility Treatment market Study:
• CAGR of the market during the forecast period 2022-2028
• In-depth information on growth factors that will accelerate the Male Infertility Treatment market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Male Infertility Treatment market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Male Infertility Treatment Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Male Infertility Treatment market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Male Infertility Treatment market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Male Infertility Treatment Device Manufacturers, Medical Device Suppliers and Distributors, Healthcare Service Providers, Research Laboratories, Government Bodies, End-Users and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • DNA Fragmentation Technique
  • Oxidative Stress Analysis
  • Microscopic Examination
  • Sperm Agglutination
  • Computer Assisted Semen Analysis
  • Sperm Penetration Assay
  • Others
By Application
  • Hospitals
  • Clinics
  • Others
By Treatment
  • Assisted Reproductive Technology
  • Varicocele Surgery
  • Medication
  • Others

By Test
  • Scrotal ultrasound
  • Transrectal ultrasound
  • Hormone testing
  • Post-ejaculation urinalysis
  • Genetic tests
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Fertility Clinics in Developing Countries
      • 3.2.2. Technological Advancements in Male Infertility Treatment Devices
    • 3.3. Market Challenges
      • 3.3.1. The High Cost of Procedures
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Sperm Donors at Sperm Banks
      • 3.4.2. Growing Awareness through Online Advertisement for Infertility Services
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Male Infertility Treatment, by Type, Application, Treatment, Test and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Male Infertility Treatment (Value)
      • 5.2.1. Global Male Infertility Treatment by: Type (Value)
        • 5.2.1.1. DNA Fragmentation Technique
        • 5.2.1.2. Oxidative Stress Analysis
        • 5.2.1.3. Microscopic Examination
        • 5.2.1.4. Sperm Agglutination
        • 5.2.1.5. Computer Assisted Semen Analysis
        • 5.2.1.6. Sperm Penetration Assay
        • 5.2.1.7. Others
      • 5.2.2. Global Male Infertility Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Male Infertility Treatment by: Treatment (Value)
        • 5.2.3.1. Assisted Reproductive Technology
        • 5.2.3.2. Varicocele Surgery
        • 5.2.3.3. Medication
        • 5.2.3.4. Others
      • 5.2.4. Global Male Infertility Treatment by: Test (Value)
        • 5.2.4.1. Scrotal ultrasound
        • 5.2.4.2. Transrectal ultrasound
        • 5.2.4.3. Hormone testing
        • 5.2.4.4. Post-ejaculation urinalysis
        • 5.2.4.5. Genetic tests
        • 5.2.4.6. Others
      • 5.2.5. Global Male Infertility Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Male Infertility Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer Healthcare (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Andrology Solutions (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aytu BioScience, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cadila Healthcare Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Halotech DNA SL (Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. EMD Sereno, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. SCSA Diagnostics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Intas Pharmaceuticals Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. The Cooper Companies Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Vitrolife AB (Sweden)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Male Infertility Treatment Sale, by Type, Application, Treatment, Test and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Male Infertility Treatment (Value)
      • 7.2.1. Global Male Infertility Treatment by: Type (Value)
        • 7.2.1.1. DNA Fragmentation Technique
        • 7.2.1.2. Oxidative Stress Analysis
        • 7.2.1.3. Microscopic Examination
        • 7.2.1.4. Sperm Agglutination
        • 7.2.1.5. Computer Assisted Semen Analysis
        • 7.2.1.6. Sperm Penetration Assay
        • 7.2.1.7. Others
      • 7.2.2. Global Male Infertility Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Male Infertility Treatment by: Treatment (Value)
        • 7.2.3.1. Assisted Reproductive Technology
        • 7.2.3.2. Varicocele Surgery
        • 7.2.3.3. Medication
        • 7.2.3.4. Others
      • 7.2.4. Global Male Infertility Treatment by: Test (Value)
        • 7.2.4.1. Scrotal ultrasound
        • 7.2.4.2. Transrectal ultrasound
        • 7.2.4.3. Hormone testing
        • 7.2.4.4. Post-ejaculation urinalysis
        • 7.2.4.5. Genetic tests
        • 7.2.4.6. Others
      • 7.2.5. Global Male Infertility Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Male Infertility Treatment: by Type(USD Million)
  • Table 2. Male Infertility Treatment DNA Fragmentation Technique , by Region USD Million (2017-2022)
  • Table 3. Male Infertility Treatment Oxidative Stress Analysis , by Region USD Million (2017-2022)
  • Table 4. Male Infertility Treatment Microscopic Examination , by Region USD Million (2017-2022)
  • Table 5. Male Infertility Treatment Sperm Agglutination , by Region USD Million (2017-2022)
  • Table 6. Male Infertility Treatment Computer Assisted Semen Analysis , by Region USD Million (2017-2022)
  • Table 7. Male Infertility Treatment Sperm Penetration Assay , by Region USD Million (2017-2022)
  • Table 8. Male Infertility Treatment Others , by Region USD Million (2017-2022)
  • Table 9. Male Infertility Treatment: by Application(USD Million)
  • Table 10. Male Infertility Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 11. Male Infertility Treatment Clinics , by Region USD Million (2017-2022)
  • Table 12. Male Infertility Treatment Others , by Region USD Million (2017-2022)
  • Table 13. Male Infertility Treatment: by Treatment(USD Million)
  • Table 14. Male Infertility Treatment Assisted Reproductive Technology , by Region USD Million (2017-2022)
  • Table 15. Male Infertility Treatment Varicocele Surgery , by Region USD Million (2017-2022)
  • Table 16. Male Infertility Treatment Medication , by Region USD Million (2017-2022)
  • Table 17. Male Infertility Treatment Others , by Region USD Million (2017-2022)
  • Table 18. Male Infertility Treatment: by Test(USD Million)
  • Table 19. Male Infertility Treatment Scrotal ultrasound , by Region USD Million (2017-2022)
  • Table 20. Male Infertility Treatment Transrectal ultrasound , by Region USD Million (2017-2022)
  • Table 21. Male Infertility Treatment Hormone testing , by Region USD Million (2017-2022)
  • Table 22. Male Infertility Treatment Post-ejaculation urinalysis , by Region USD Million (2017-2022)
  • Table 23. Male Infertility Treatment Genetic tests , by Region USD Million (2017-2022)
  • Table 24. Male Infertility Treatment Others , by Region USD Million (2017-2022)
  • Table 25. South America Male Infertility Treatment, by Country USD Million (2017-2022)
  • Table 26. South America Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 27. South America Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 28. South America Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 29. South America Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 30. Brazil Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 31. Brazil Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 32. Brazil Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 33. Brazil Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 34. Argentina Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 35. Argentina Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 36. Argentina Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 37. Argentina Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 38. Rest of South America Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 39. Rest of South America Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 40. Rest of South America Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 41. Rest of South America Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 42. Asia Pacific Male Infertility Treatment, by Country USD Million (2017-2022)
  • Table 43. Asia Pacific Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 44. Asia Pacific Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 45. Asia Pacific Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 46. Asia Pacific Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 47. China Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 48. China Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 49. China Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 50. China Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 51. Japan Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 52. Japan Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 53. Japan Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 54. Japan Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 55. India Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 56. India Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 57. India Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 58. India Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 59. South Korea Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 60. South Korea Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 61. South Korea Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 62. South Korea Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 63. Australia Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 64. Australia Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 65. Australia Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 66. Australia Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 71. Europe Male Infertility Treatment, by Country USD Million (2017-2022)
  • Table 72. Europe Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 73. Europe Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 74. Europe Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 75. Europe Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 76. Germany Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 77. Germany Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 78. Germany Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 79. Germany Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 80. France Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 81. France Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 82. France Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 83. France Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 84. Italy Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 85. Italy Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 86. Italy Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 87. Italy Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 88. United Kingdom Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 89. United Kingdom Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 90. United Kingdom Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 91. United Kingdom Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 92. Netherlands Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 93. Netherlands Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 94. Netherlands Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 95. Netherlands Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 96. Rest of Europe Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 97. Rest of Europe Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 98. Rest of Europe Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 99. Rest of Europe Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 100. MEA Male Infertility Treatment, by Country USD Million (2017-2022)
  • Table 101. MEA Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 102. MEA Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 103. MEA Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 104. MEA Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 105. Middle East Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 106. Middle East Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 107. Middle East Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 108. Middle East Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 109. Africa Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 110. Africa Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 111. Africa Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 112. Africa Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 113. North America Male Infertility Treatment, by Country USD Million (2017-2022)
  • Table 114. North America Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 115. North America Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 116. North America Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 117. North America Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 118. United States Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 119. United States Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 120. United States Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 121. United States Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 122. Canada Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 123. Canada Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 124. Canada Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 125. Canada Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 126. Mexico Male Infertility Treatment, by Type USD Million (2017-2022)
  • Table 127. Mexico Male Infertility Treatment, by Application USD Million (2017-2022)
  • Table 128. Mexico Male Infertility Treatment, by Treatment USD Million (2017-2022)
  • Table 129. Mexico Male Infertility Treatment, by Test USD Million (2017-2022)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Male Infertility Treatment: by Type(USD Million)
  • Table 141. Male Infertility Treatment DNA Fragmentation Technique , by Region USD Million (2023-2028)
  • Table 142. Male Infertility Treatment Oxidative Stress Analysis , by Region USD Million (2023-2028)
  • Table 143. Male Infertility Treatment Microscopic Examination , by Region USD Million (2023-2028)
  • Table 144. Male Infertility Treatment Sperm Agglutination , by Region USD Million (2023-2028)
  • Table 145. Male Infertility Treatment Computer Assisted Semen Analysis , by Region USD Million (2023-2028)
  • Table 146. Male Infertility Treatment Sperm Penetration Assay , by Region USD Million (2023-2028)
  • Table 147. Male Infertility Treatment Others , by Region USD Million (2023-2028)
  • Table 148. Male Infertility Treatment: by Application(USD Million)
  • Table 149. Male Infertility Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 150. Male Infertility Treatment Clinics , by Region USD Million (2023-2028)
  • Table 151. Male Infertility Treatment Others , by Region USD Million (2023-2028)
  • Table 152. Male Infertility Treatment: by Treatment(USD Million)
  • Table 153. Male Infertility Treatment Assisted Reproductive Technology , by Region USD Million (2023-2028)
  • Table 154. Male Infertility Treatment Varicocele Surgery , by Region USD Million (2023-2028)
  • Table 155. Male Infertility Treatment Medication , by Region USD Million (2023-2028)
  • Table 156. Male Infertility Treatment Others , by Region USD Million (2023-2028)
  • Table 157. Male Infertility Treatment: by Test(USD Million)
  • Table 158. Male Infertility Treatment Scrotal ultrasound , by Region USD Million (2023-2028)
  • Table 159. Male Infertility Treatment Transrectal ultrasound , by Region USD Million (2023-2028)
  • Table 160. Male Infertility Treatment Hormone testing , by Region USD Million (2023-2028)
  • Table 161. Male Infertility Treatment Post-ejaculation urinalysis , by Region USD Million (2023-2028)
  • Table 162. Male Infertility Treatment Genetic tests , by Region USD Million (2023-2028)
  • Table 163. Male Infertility Treatment Others , by Region USD Million (2023-2028)
  • Table 164. South America Male Infertility Treatment, by Country USD Million (2023-2028)
  • Table 165. South America Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 166. South America Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 167. South America Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 168. South America Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 169. Brazil Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 170. Brazil Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 171. Brazil Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 172. Brazil Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 173. Argentina Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 174. Argentina Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 175. Argentina Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 176. Argentina Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 177. Rest of South America Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 178. Rest of South America Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 179. Rest of South America Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 180. Rest of South America Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 181. Asia Pacific Male Infertility Treatment, by Country USD Million (2023-2028)
  • Table 182. Asia Pacific Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 183. Asia Pacific Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 184. Asia Pacific Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 185. Asia Pacific Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 186. China Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 187. China Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 188. China Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 189. China Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 190. Japan Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 191. Japan Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 192. Japan Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 193. Japan Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 194. India Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 195. India Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 196. India Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 197. India Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 198. South Korea Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 199. South Korea Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 200. South Korea Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 201. South Korea Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 202. Australia Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 203. Australia Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 204. Australia Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 205. Australia Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 209. Rest of Asia-Pacific Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 210. Europe Male Infertility Treatment, by Country USD Million (2023-2028)
  • Table 211. Europe Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 212. Europe Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 213. Europe Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 214. Europe Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 215. Germany Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 216. Germany Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 217. Germany Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 218. Germany Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 219. France Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 220. France Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 221. France Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 222. France Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 223. Italy Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 224. Italy Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 225. Italy Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 226. Italy Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 227. United Kingdom Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 228. United Kingdom Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 229. United Kingdom Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 230. United Kingdom Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 231. Netherlands Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 232. Netherlands Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 233. Netherlands Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 234. Netherlands Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 235. Rest of Europe Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 236. Rest of Europe Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 237. Rest of Europe Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 238. Rest of Europe Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 239. MEA Male Infertility Treatment, by Country USD Million (2023-2028)
  • Table 240. MEA Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 241. MEA Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 242. MEA Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 243. MEA Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 244. Middle East Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 245. Middle East Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 246. Middle East Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 247. Middle East Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 248. Africa Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 249. Africa Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 250. Africa Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 251. Africa Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 252. North America Male Infertility Treatment, by Country USD Million (2023-2028)
  • Table 253. North America Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 254. North America Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 255. North America Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 256. North America Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 257. United States Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 258. United States Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 259. United States Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 260. United States Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 261. Canada Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 262. Canada Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 263. Canada Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 264. Canada Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 265. Mexico Male Infertility Treatment, by Type USD Million (2023-2028)
  • Table 266. Mexico Male Infertility Treatment, by Application USD Million (2023-2028)
  • Table 267. Mexico Male Infertility Treatment, by Treatment USD Million (2023-2028)
  • Table 268. Mexico Male Infertility Treatment, by Test USD Million (2023-2028)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Male Infertility Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Male Infertility Treatment: by Application USD Million (2017-2022)
  • Figure 6. Global Male Infertility Treatment: by Treatment USD Million (2017-2022)
  • Figure 7. Global Male Infertility Treatment: by Test USD Million (2017-2022)
  • Figure 8. South America Male Infertility Treatment Share (%), by Country
  • Figure 9. Asia Pacific Male Infertility Treatment Share (%), by Country
  • Figure 10. Europe Male Infertility Treatment Share (%), by Country
  • Figure 11. MEA Male Infertility Treatment Share (%), by Country
  • Figure 12. North America Male Infertility Treatment Share (%), by Country
  • Figure 13. Global Male Infertility Treatment share by Players 2022 (%)
  • Figure 14. Global Male Infertility Treatment share by Players (Top 3) 2022(%)
  • Figure 15. Global Male Infertility Treatment share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bayer Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Bayer Healthcare (Germany) Revenue: by Geography 2022
  • Figure 19. Andrology Solutions (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Andrology Solutions (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Aytu BioScience, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Aytu BioScience, Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Cadila Healthcare Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 24. Cadila Healthcare Ltd. (India) Revenue: by Geography 2022
  • Figure 25. Halotech DNA SL (Spain) Revenue, Net Income and Gross profit
  • Figure 26. Halotech DNA SL (Spain) Revenue: by Geography 2022
  • Figure 27. EMD Sereno, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. EMD Sereno, Inc. (United States) Revenue: by Geography 2022
  • Figure 29. SCSA Diagnostics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. SCSA Diagnostics, Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Intas Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. Intas Pharmaceuticals Ltd. (India) Revenue: by Geography 2022
  • Figure 33. The Cooper Companies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. The Cooper Companies Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Vitrolife AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 36. Vitrolife AB (Sweden) Revenue: by Geography 2022
  • Figure 37. Global Male Infertility Treatment: by Type USD Million (2023-2028)
  • Figure 38. Global Male Infertility Treatment: by Application USD Million (2023-2028)
  • Figure 39. Global Male Infertility Treatment: by Treatment USD Million (2023-2028)
  • Figure 40. Global Male Infertility Treatment: by Test USD Million (2023-2028)
  • Figure 41. South America Male Infertility Treatment Share (%), by Country
  • Figure 42. Asia Pacific Male Infertility Treatment Share (%), by Country
  • Figure 43. Europe Male Infertility Treatment Share (%), by Country
  • Figure 44. MEA Male Infertility Treatment Share (%), by Country
  • Figure 45. North America Male Infertility Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer Healthcare (Germany)
  • Andrology Solutions (United Kingdom)
  • Aytu BioScience, Inc. (United States)
  • Cadila Healthcare Ltd. (India)
  • Halotech DNA SL (Spain)
  • EMD Sereno, Inc. (United States)
  • SCSA Diagnostics, Inc. (United States)
  • Intas Pharmaceuticals Ltd. (India)
  • The Cooper Companies Inc. (United States)
  • Vitrolife AB (Sweden)
Additional players considered in the study are as follows:
Cook Group Incorporated (United States) , Esco Micro Pte. Ltd. (Singapore) , Thermo Fisher Scientific, Inc. (United States) , Others
Select User Access Type

Key Highlights of Report


Jul 2023 208 Pages 90 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Male Infertility Treatment Quantitative research analysis
Male Infertility Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Male Infertility Treatment Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Male Infertility Treatment market is dominated by United States Players and may generate healthy valuation by 2028.
  • Rising Number of Fertility Clinics in Developing Countries
  • Technological Advancements in Male Infertility Treatment Devices
dominated the Male Infertility Treatment market. This is attributable to growing trend of "Increasing Number of Sperm Donors at Sperm Banks "

Know More About Male Infertility Treatment Report?

Have a Query? Click Here

Other Related Reports

Jet Lag Treatment Comprehensive Study by Type (Light therapy, Medications), Application (Hospital Pharmacies, Retail Pharmacies, Online Sales, Drug Stores), Drug (Prescription drugs, Melatonin, Her...
$ 3650
Medical Device Cleaning Comprehensive Study by Type (Automatic Cleaning, Manual Cleaning), Application (Hospital, Clinics, Others), Product Type (Enzymatic Detergents, Non-enzymatic Detergents, Alkal...
$ 3650
Animal Model Services Comprehensive Study by Type (Mice, Rats, Fish, Birds, Cattles, Others), Application (Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genet...
$ 3750
Gastrointestinal Cancer Treatment Comprehensive Study by Drug Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Therapy (Immunotherapy, Chemother...
$ 3750
Veterinary Medication Comprehensive Study by Type (Biologics, Pharmaceuticals, Medicated Feed Additives), Deployment Mode (Oral, Parenteral, Suspension, Topical, Carrier), Distribution Channel (Veter...
$ 3800
Advance Wound Care Comprehensive Study by Type (Hydrogels, Hydrocolloids, Foams, Fabrics, Sponges, Alginates), Application (Inpatient Facilities, Outpatient Facilities), Wound types (Penetrating woun...
$ 3750